4//SEC Filing
Goff Brian 4
Accession 0001439222-25-000015
CIK 0001439222other
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 4:10 PM ET
Size
18.9 KB
Accession
0001439222-25-000015
Insider Transaction Report
Form 4
Goff Brian
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common stock
2025-03-01+8,500→ 87,292 total - Sale
Common stock
2025-03-03$35.54/sh−4,153$147,598→ 83,139 total - Exercise/Conversion
Common stock
2025-03-01+18,000→ 101,139 total - Sale
Common stock
2025-03-03$35.54/sh−8,794$312,539→ 92,345 total - Award
Stock options (right to buy)
2025-03-01+142,500→ 142,500 totalExercise: $35.54Exp: 2035-03-01→ Common stock (142,500 underlying) - Exercise/Conversion
Restricted stock units
2025-03-01−8,500→ 8,500 total→ Common stock (8,500 underlying) - Exercise/Conversion
Restricted stock units
2025-03-01−18,000→ 36,000 total→ Common stock (18,000 underlying) - Award
Restricted stock units
2025-03-01+39,000→ 39,000 total→ Common stock (39,000 underlying)
Footnotes (7)
- [F1]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023.
- [F2]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024.
- [F3]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- [F4]The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.
- [F5]This option was granted on March 1, 2025. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- [F6]The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.
- [F7]The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments.
Documents
Issuer
AGIOS PHARMACEUTICALS, INC.
CIK 0001439222
Entity typeother
Related Parties
1- filerCIK 0001546216
Filing Metadata
- Form type
- 4
- Filed
- Mar 3, 7:00 PM ET
- Accepted
- Mar 4, 4:10 PM ET
- Size
- 18.9 KB